Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIP-207
- Development stage
- Preclinical
- Lead developer
- AIP Medical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AIP-207 is a preclinical-stage radiopharmaceutical diagnostic candidate being developed by AIP Medical (Advanced Innovative Partners). It is specifically designed for the detection and imaging of Glioblastoma Multiforme (GBM), an aggressive primary brain tumor. As a radiopharmaceutical diagnostic, AIP-207 is intended to utilize a radioisotope-labeled targeting molecule to provide high-contrast visualization of tumor cells, potentially aiding in the diagnosis, staging, or surgical planning for patients with GBM. The specific molecular target and radioisotope used in the formulation have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on AIP-207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIP-207.